title: Assessment of cyclosporine therapeutic monitoring with C2 concentrations in stable renal allograft recipients.
abstract: The optimal long-term C2 target to minimize the risk of chronic allograft nephropathy (CAN) has not yet been established in a prospective study. Furthermore, it is not known whether the target is the same in patients who also receive mycophenolate mofetil (MMF). We determined the 2-hour postdose concentration (C2) in a cohort of 65 maintenance renal transplant patients. The mean C0 level was 0.12 microg/mL and the C2 was 0.62 microg/mL. The overexposed patients are 14%. There was a good correlation between C0 and C2, and between C2 and the cyclosporine (CsA) dose. Patients receiving MMF display lower levels of C0 and C2, lower dosages of CsA, and higher levels of plasma creatinines. We did not observe significant differences on relating the level of absorption to patient age and sex, creatinine level, CsA dose, or coadministration of MMF. In conclusion, there is a low incidence of overexposed patients. C2 levels of approximately 0.6 microg/mL (and possibly may be sufficient in renal transplant patients. somewhat lower [0.5 microg/mL] in patients receiving MMF) Patients who display slow or fast absorption of CsA do not have any apparent characteristic.
authors.affiliation: Renal Transplant Unit, Department of Nephrology, Fundació Puigvert, Universitat Autónoma, Barcelona, Spain. jdiaz@fundacio-puigvert.es
authors.forename: J M
authors.initials: JM
authors.lastname: Díaz
authors.forename: Z
authors.initials: Z
authors.lastname: Sainz
authors.forename: L L
authors.initials: LL
authors.lastname: Guirado
authors.forename: R
authors.initials: R
authors.lastname: Montañés
authors.forename: M
authors.initials: M
authors.lastname: Picazo
authors.forename: R
authors.initials: R
authors.lastname: García-Camín
authors.forename: A
authors.initials: A
authors.lastname: Alcaraz
authors.forename: R
authors.initials: R
authors.lastname: Solà
mesh_terms: D000328:Adult; D000368:Aged; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016903:Drug Monitoring / Q000379:methods; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D003404:Creatinine; D009173:Mycophenolic Acid